GALNT10 and hepatocellular carcinoma: GALNT10-deficient cells were more sensitive to both sorafenib and doxorubicin treatment as evidenced by significantly elevated cell apoptosis, suggesting the potential of GALNT10 as a therapeutic target for HCC [23].